Local myotoxicity from sustained release of bupivacaine from microparticles. - Wikidata - wikimedia - TriplyDB

Local myotoxicity from sustained release of bupivacaine from microparticles.

Local myotoxicity from sustained release of bupivacaine from microparticles.

http://www.wikidata.org/entity/Q34773144

about

Prolonged duration local anesthesia with minimal toxicity Multivesicular liposomal bupivacaine at the sciatic nerve.Safety Evaluation of EXPAREL (DepoFoam Bupivacaine) Administered by Repeated Subcutaneous Injection in Rabbits and Dogs: Species Comparison.The quaternary lidocaine derivative QX-314 in combination with bupivacaine for long-lasting nerve block: Efficacy, toxicity, and the optimal formulation in rats.Prolonged nerve blockade delays the onset of neuropathic pain Local toxicity from local anesthetic polymeric microparticles Long-term effect of ropivacaine nanoparticles for sciatic nerve block on postoperative pain in rats.A Content Incontinent: Report of Liposomal Bupivacaine Induced Fecal Incontinence.Review of prolonged local anesthetic action.Extended release formulations for local anaesthetic agents.An in-vivo evaluation of a MEMS drug delivery device using Kunming mice model.Nanogel scavengers for drugs: local anesthetic uptake by thermoresponsive nanogels.Tetrodotoxin-bupivacaine-epinephrine combinations for prolonged local anesthesia Ultrasensitive Phototriggered Local Anesthesia.Toxicogenomic analysis of a sustained release local anesthetic delivery system.Rotator cuff healing after continuous subacromial bupivacaine infusion: an in vivo rabbit study.Drug delivery systems for prolonged duration local anesthesia.Prolonged Duration Local Anesthesia Using Liposomal Bupivacaine Combined With Liposomal Dexamethasone and Dexmedetomidine.Ultrasound-triggered liposomes for on-demand local anesthesia.Tetrodotoxin, Epinephrine, and Chemical Permeation Enhancer Combinations in Peripheral Nerve Blockade.Bupivacaine induces short-term alterations and impairment in rat tendons.Controlled release of bupivacaine HCl through microchannels of biodegradable drug delivery device.Involvement of superoxide generated by NADPH oxidase in the shedding of procoagulant vesicles from human monocytic cells exposed to bupivacaine.In vivo study of an extended release bupivacaine formulation following site-directed nerve injection Addressing the Issue of Tetrodotoxin Targeting

P2860

Q24648933-A9ECCCF9-C3BA-4A2B-88C7-7857BA4AA2AE Q35115768-10478A44-9C3C-4A86-81C6-3F832BFF1677 Q35294846-AD247602-1E32-49C5-B1C8-4002F2404623 Q36320027-104B6090-E733-4E95-A356-04061746EB46 Q36378557-0C31665E-04B0-48FE-A32F-B9E6470FAD73 Q36711380-7FE425A1-63E8-4A60-BA75-3F7639B3EB6D Q36926492-15DE9A13-D248-4714-979B-C5B0491CA524 Q37322591-8DF169C0-6C46-4FCB-9C9B-402B57B94AB9 Q37735192-26F6A864-0F91-4F7E-8855-FD30DC804327 Q38011267-3336B2B3-0D7F-420E-A9BD-A5EB0CD077F5 Q39042984-1ED49203-686B-4AD4-A644-F2088CFA193B Q39412465-FE7A5833-9F02-4FAB-9D75-B8EB9473FD9F Q41166944-35A4FA0A-9D2E-4390-96E9-D4BB6D412394 Q42115101-6FEDDBD5-F9F3-49DC-92DA-A03461BD5BD0 Q42632463-389018E3-3766-45B7-99D8-582C46C60F22 Q42639306-D46A98D3-3513-4B7A-B0B5-53E7676B6D03 Q47100619-D00151D2-FD61-47F9-A48C-E3BC5F2B04C6 Q47221003-902963FB-D370-4135-95CC-2F28CC0E03C7 Q47223227-B4DC90A2-388B-46AF-90BB-B8A99D2B3F94 Q47301962-2286B705-3CC0-44DD-93CA-4A2CB8978839 Q48009884-D5DCAA64-3FF5-417E-BA4F-8C7232A1D190 Q48183017-2EDEA305-0FA8-4F10-8940-62BE57640DDC Q48218398-8FF32A08-1222-464F-91BE-B20673125020 Q57920702-0D2CE147-5338-4E1F-9513-C09B4BFEFA9E Q58692119-9F54B9B4-0CAE-41D0-B257-602C846075EA

P2860

Local myotoxicity from sustained release of bupivacaine from microparticles.

http://www.wikidata.org/entity/Q34773144

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Local myotoxicity from sustained release of bupivacaine from microparticles.

@ast

Local myotoxicity from sustained release of bupivacaine from microparticles.

@en

Local myotoxicity from sustained release of bupivacaine from microparticles.

@nl

type

label

Local myotoxicity from sustained release of bupivacaine from microparticles.

@ast

Local myotoxicity from sustained release of bupivacaine from microparticles.

@en

Local myotoxicity from sustained release of bupivacaine from microparticles.

@nl

prefLabel

Local myotoxicity from sustained release of bupivacaine from microparticles.

@ast

Local myotoxicity from sustained release of bupivacaine from microparticles.

@en

Local myotoxicity from sustained release of bupivacaine from microparticles.

@nl

P1433

Q34773144-1C78C4F4-24D5-4099-A043-3710BE563CAE

P1476

Q34773144-01CD6E7A-B608-4423-BDEB-079EBBEDF644

P2093

Q34773144-227A751F-B6C6-4A09-B773-8D517110A1BD

Q34773144-70A34175-3091-4486-8BAC-46021099B50C

Q34773144-8916786F-177F-43BF-9A2C-371FC354819F

Q34773144-9A7E3D6B-E94E-480E-B44D-D19BDB1D3790

Q34773144-B50688BB-3990-410E-B890-92E4FDC9A2E6

P2860

Q34773144-000C5D46-1A3E-4E1D-8CBA-587D39C2499A

Q34773144-0553A14F-682B-49C3-831C-7C0A1ACB83EE

Q34773144-10464F17-AFF9-455D-94FF-3981CB366B90

Q34773144-1365FAEB-C660-4E33-ABD4-3AA375CBED03

Q34773144-189D7342-F49E-478A-853B-B42592F6C2AF

Q34773144-1EACC5DC-4EC0-4A83-8BFC-15908B849E7D

Q34773144-2B95423C-B581-4CB9-9774-9E277CAE43DF

Q34773144-3053BCC1-63E4-40B3-9514-75A5BD1087DC

Q34773144-34E3C8D8-CD4C-4D63-B5F0-E53FCBD887A9

Q34773144-3569E7CA-0F44-43C1-A376-559060556575

P304

Q34773144-468778C4-CC72-416C-8F5E-6A95304CA9ED

P31

Q34773144-5BAF8E38-4686-49BD-9FF0-DF4115026ABD

P356

Q34773144-7024D748-45CD-420B-86CE-E1D4FE6AA5EA

P407

Q34773144-D0184EDC-14DA-4F0E-8C59-6B3782D5EA90

P433

Q34773144-467C4772-784A-4E35-87F6-76C39AB90390

P478

Q34773144-990501D4-B5C8-4299-B5AA-DC976D058AD2

P577

Q34773144-A8757A75-7888-403F-AD54-87BF81887F6A

P698

Q34773144-D7F00AAC-0656-4E47-9656-30C15594C62F

P932

Q34773144-DFEBF133-D96A-4365-99BE-35AD9771E7F9

P356

ALN.0B013E31816C8A48

P1433

P1476

Local myotoxicity from sustained release of bupivacaine from microparticles.

@en

P2093

Daniel S Kohane

http://www.w3.org/2001/XMLSchema#string

Daphne Hao

http://www.w3.org/2001/XMLSchema#string

Evangelia Bellas

http://www.w3.org/2001/XMLSchema#string

Julie Y Tse

http://www.w3.org/2001/XMLSchema#string

Robert Padera

http://www.w3.org/2001/XMLSchema#string

P2860

Tetrodotoxin for prolonged local anesthesia with minimal myotoxicity.

Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres.

Prolonged regional nerve blockade by controlled release of local anesthetic from a biodegradable polymer matrix.

Local myotoxicity of bupivacaine in rabbits after continuous supraclavicular brachial plexus block.

Local anesthetic myotoxicity: a case and review.

Prolonged analgesia with liposomal bupivacaine in a mouse model.

Relative neural toxicity of local anesthetics.

Lipid-sugar particles for intracranial drug delivery: safety and biocompatibility.

Water-diluted local anesthetic for trigger-point injection in chronic myofascial pain syndrome: evaluation of types of local anesthetic and concentrations in water.

Biocompatibility of lipid-protein-sugar particles containing bupivacaine in the epineurium.

P304

921-928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/ALN.0B013E31816C8A48

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18431129

http://www.w3.org/2001/XMLSchema#string

P932

3939710

http://www.w3.org/2001/XMLSchema#string